Cargando…
Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
BACKGROUND: Bilastine is a novel second-generation H(1) antihistamine, which has not shown sedative or cardiotoxic effects in clinical trials and in post-marketing experience so far, developed for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. It has recently been granted m...
Autores principales: | Lasseter, Kenneth C., Sologuren, Ander, La Noce, Anna, Dilzer, Stacy C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751212/ https://www.ncbi.nlm.nih.gov/pubmed/23873362 http://dx.doi.org/10.1007/s40261-013-0110-0 |
Ejemplares similares
-
Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions
por: Leceta, Amalia, et al.
Publicado: (2021) -
Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department
por: Leceta, Amalia, et al.
Publicado: (2017) -
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
por: Vajda, Eric G., et al.
Publicado: (2016) -
Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016) -
Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)